Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
25th July 2017
In just five years patients across England could be waiting more than a week for an appointment with a GP or practice nurse on more than 100 million occasions, according to a new projection by the Royal College of GPs.
25th July 2017
European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
25th July 2017
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
25th July 2017
GlaxoSmithKline and Innoviva have applied to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy.
24th July 2017
NHS England has unveiled detailed proposals of how prescriptions for “ineffective, over-priced and low value treatments” will be cut in order to shave millions off of the NHS’ drugs bill.
24th July 2017
Patients with Merkel Cell Carcinoma living in the UK are a step closer to getting early access to Merck and Pfizer’s avelumab after regulators assigned the drug Promising Innovative Medicines (PIM) status.
24th July 2017
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
24th July 2017
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
21st July 2017
European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.
21st July 2017
The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
21st July 2017
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
21st July 2017
If the answer is yes, take the first step toward getting your hands on the coveted Pharma by entering your Commercial Cross Functional Team into Marketer of the Year, today!
21st July 2017
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
20th July 2017
Patients living with multiple myeloma across England and Wales should now get ‘routine’ access to Amgen’s Kyprolis on the NHS within three months following a final green light from the National Institute for Health and Care Excellence.
20th July 2017
